ArticleMolecular cancer therapeutics2017
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Optimizing local control in the surgical management of bladder cancer.Nature reviews. Urology · 2026Review
- Review
- Liquid Chromatography-Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment.Chemical research in toxicology · 2023Article
- Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy.Molecular therapy oncolytics · 2023Article
- Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?Clinical and translational science · 2022Review
- Preclinical Models for Bladder Cancer Research.Hematology/oncology clinics of North America · 2021Review
- Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.Cancer letters · 2021Article
- RNA Targeting in Acute Myeloid Leukemia.ACS pharmacology & translational science · 2020Article
- Phase 0/microdosing approaches: time for mainstream application in drug development?Nature reviews. Drug discovery · 2020Review
- Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.Molecular cancer therapeutics · 2020Article
- Methods and Challenges for Computational Data Analysis for DNA Adductomics.Chemical research in toxicology · 2019Article
- Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice.International journal of molecular sciences · 2019Article
- Fidelity of a PDX-CR model for bladder cancer.Biochemical and biophysical research communications · 2019Article
- Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science.Toxics · 2019Review
- Naphthalene genotoxicity: DNA adducts in primate and mouse airway explants.Toxicology letters · 2019Article
- Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.Chemical research in toxicology · 2018Article
- Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.Chemical research in toxicology · 2018Article
- COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.Molecular cancer therapeutics · 2018Article
- A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.International journal of cancer · 2017Article
- DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Chemical research in toxicology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
Maike ZimmermannDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Si-Si WangDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Hongyong ZhangDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Tzu-Yin LinDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Michael MalfattiLawrence Livermore National Laboratory, Livermore, California.
Kurt HaackLawrence Livermore National Laboratory, Livermore, California.
Ted OgnibeneLawrence Livermore National Laboratory, Livermore, California.
Hongyuan YangThe Jackson Laboratory, Sacramento, California.
Susan AirhartThe Jackson Laboratory, Sacramento, California.
Kenneth W TurteltaubLawrence Livermore National Laboratory, Livermore, California.
George D CiminoAccelerated Medical Diagnostics Incorporated, Berkeley, California.
Clifford G TepperDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, California.
Alexandra DrakakiDivision of Hematology and Oncology, UCLA Medical Center, Los Angeles, California.
Karim ChamieDepartment of Urology, UCLA Medical Center, Los Angeles, California.
Ralph de Vere WhiteDepartment of Urology, University of California Davis, Sacramento, California.
Chong-Xian PanDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. phenderson@ucdavis.edu cxpan@ucdavis.edu.
Paul T HendersonDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. phenderson@ucdavis.edu cxpan@ucdavis.edu.
Lawrence Livermore National Laboratory · USExcel Diagnostics Imaging · USUniversity of California Davis Medical Center · USJackson Laboratory · USUCLA Medical Center · USUniversity of California, Davis · USVA Northern California Health Care System · US
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9MVITAMIN C (ASCORBATE) METABOLISM IN DROSPHILA MELANOGASTERP41RR013461 · NCRR · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI HASKELL, MARJORIE J · 1999 to 2011
$20.8MResource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)P41GM103483 · NIGMS · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI TURTELTAUB, KENNETH W. · 2012 to 2019
$12.0MNCI NIH HHS HHSN261201000133CNCI NIH HHS HHSN261201200048CNCI NIH HHS P30 CA093373NCRR NIH HHS P41 RR013461NIGMS NIH HHS P41 GM103483
Abstract
We report progress on predicting tumor response to platinum-based chemotherapy with a novel mass spectrometry approach. Fourteen bladder cancer patients were administered one diagnostic microdose each of [
Indexed as
BiomarkersDNA AdductsDrug Resistance, NeoplasmAnimalsAntineoplastic AgentsCarboplatinCell Line, TumorDeoxycytidineDisease Models, AnimalDNA RepairDrug SynergismFemaleGemcitabineHumansMass SpectrometryMiceAntineoplastic AgentsBiomarkersCarboplatincarboplatin-DNA adductDeoxycytidineDNA AdductsGemcitabinePlatinum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.